Daiichi Sankyo Company, Limited: DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society
(1)
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005385/en/
Despite recent advances in targeted treatment, five-year survival rates for both renal cell carcinoma and ovarian cancer remain low and new therapeutic strategies are needed for tumors that continue to progress on currently available medicines.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute
February 2, 2021 GMT
TOKYO & MUNICH & BASKING RIDGE, N.J. & NASHVILLE, Tenn. (BUSINESS WIRE) Feb 2, 2021
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Sarah Cannon Promotes Melissa Johnson, MD, to Program Director, Lung Cancer Research
December 17, 2020 GMT
NASHVILLE, Tenn. (BUSINESS WIRE) Dec 17, 2020
Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
“Since joining Sarah Cannon, Dr. Johnson’s contributions to research have helped transform the treatment options available to patients facing lung cancer,” said David Spigel, MD, Chief Scientific Officer, Sarah Cannon. “As Program Director of Lung Cancer Research, Dr. Johnson will continue to help advance therapies for our patients today and in the future.”